Article
Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories.
International journal of molecular sciences - 29 Apr 2016
Qiu Ping, Pang Ling, Arreaza Gladys, Maguire Maureen, Chang Ken C N, Marton Matthew J, Levitan Diane
Abstract excerpt
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. Several independent studies suggest that higher non-synonymous mutational burden assessed by whole exome sequencing (WES) in tumors is associated with improved objective response, durable clinical benefit, and progression-free survival in immune checkpoint inhibitors treatment. Next-generation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
